KSK120
KSK120 is a potent inhibitor of drug-resistant infections with specific activity against Chlamydia trachomatis (C. trachomatis). KSK120 inhibits the developmental cycle of C. trachomatis, thereby reducing the infectivity of progeny bacteria. KSK120 targets the glucose-6-phosphate (G-6P) metabolic pathway of C. trachomatis, showing its potential application in antimicrobial inhibition. The mechanism of KSK120 may involve inhibition of the transcriptional machinery, which provides new ideas for the development of specific drugs against C. trachomatis infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1638100-63-6
- Formule: C28H22N2O2S
- Masse moléculaire:450.55
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | EC50 |
1.25 μM
Compound: 1; KSK 120
|
Antimicrobial activity against Chlamydia trachomatis serovar LGV-L2 infected in human HeLa cells measured 44 to 48 hrs post infection by DAPI staining-based assay
Antimicrobial activity against Chlamydia trachomatis serovar LGV-L2 infected in human HeLa cells measured 44 to 48 hrs post infection by DAPI staining-based assay
|
[PMID: 26849778] |
| HeLa | EC50 |
254 nM
Compound: 1; KSK 120
|
Antimicrobial activity against Chlamydia trachomatis serovar LGV-L2 infected in human HeLa cells assessed as decrease in relative inclusion forming units measured 44 to 48 hrs post infection by DAPI staining-based assay
Antimicrobial activity against Chlamydia trachomatis serovar LGV-L2 infected in human HeLa cells assessed as decrease in relative inclusion forming units measured 44 to 48 hrs post infection by DAPI staining-based assay
|
[PMID: 26849778] |
Chemical Information
-
CAS No. 1638100-63-6
-
Masse moléculaire 450.55
-
Formule C28H22N2O2S
-
SMILES
O=C(C=C1CC2=CC=CC3=C2C=CC=C3)N4C(C(NC5=CC=CC=C5)=O)=CSC4=C1C6CC6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KSK120 Related Classifications
HY-117746 Related Classifications
Powered by Bioz